Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinomaMatthew H G Katz, Gina R Petroni, Todd Bauer, Matthew J Reilley, Brian M Wolpin, Chee-Chee Stucky, Tanios S Bekaii-Saab, Rawad Elias, Nipun Merchant, Andressa Dias Costa, Patrick Lenehan, Victoire Cardot-Ruffino, Scott Rodig, Kathleen Pfaff, Stephanie K DouganSee the full list of authors
1 December 2023
Methylglyoxal from gut microbes boosts radiosensitivity and radioimmunotherapy in rectal cancer by triggering endoplasmic reticulum stress and cGAS-STING activationHan Zhou, Lei Wang, Zhiwen Lin, Chenwei Jiang, Xingte Chen, Kai Wang, Libin Liu, Lingdong Shao, Jianji Pan, Jinluan Li, Da Zhang, Junxin Wu
30 November 2023
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumorsTodd M Bauer, Armando Santoro, Chia-Chi Lin, Ignacio Garrido-Laguna, Markus Joerger, Richard Greil, Anna Spreafico, Thomas Yau, Maria-Elisabeth Goebeler, Marie Luise Hütter-Krönke, Antonella Perotti, Pierre-Eric Juif, Darlene Lu, Louise Barys, Viviana CremascoSee the full list of authors
29 November 2023
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)Benedetta Pellegrino, Chiara Tommasi, Olga Serra, Stefania Gori, Elisabetta Cretella, Massimo Ambroggi, Antonio Frassoldati, Giancarlo Bisagni, Chiara Casarini, Emilio Bria, Luisa Carbognin, Elena Fiorio, Antonella Mura, Claudio Zamagni, Lorenzo GianniSee the full list of authors
28 November 2023
High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapyDingpei Han, Yichao Han, Wei Guo, Wei Wei, Su Yang, Jie Xiang, Jiaming Che, Lianggang Zhu, Junbiao Hang, Tom van den Ende, Hanneke W M van Laarhoven, Bin Li, Youqiong Ye, Hecheng Li
28 November 2023
CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinomaRuonan Zhang, Jie Wang, Yu Du, Ze Yu, Yihan Wang, Yixiao Jiang, Yixin Wu, Ting Le, Ziqi Li, Guoqiang Zhang, Lei Lv, Haijie Ma
24 November 2023
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumorsMarkus Joerger, Emiliano Calvo, Heinz Laubli, Juanita Lopez, Guzmán Alonso, Elena Corral de la Fuente, Dagmar Hess, David König, Vicky Sanchez Perez, Christoph Bucher, Sangeeta Jethwa, Elena Garralda
21 November 2023
Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistanceJamaal L James, Brandie C Taylor, Margaret L Axelrod, Xiaopeng Sun, Lindsey N Guerin, Paula I Gonzalez-Ericsson, Yu Wang, Violeta Sanchez, Catherine C Fahey, Melinda E Sanders, Yaomin Xu, Emily Hodges, Douglas B Johnson, Justin M Balko
20 November 2023
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapyChristina Kober, Julian Roewe, Norbert Schmees, Lars Roese, Ulrike Roehn, Benjamin Bader, Detlef Stoeckigt, Florian Prinz, Mátyás Gorjánácz, Helge Gottfried Roider, Catherine Olesch, Gabriele Leder, Horst Irlbacher, Ralf Lesche, Julien LefrancSee the full list of authors
14 November 2023
Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influxShipra Gandhi, Mateusz Opyrchal, Melissa J Grimm, Ronald T Slomba, Kathleen M Kokolus, Agnieszka Witkiewicz, Kristopher Attwood, Adrienne Groman, Lauren Williams, Mary Lynne Tarquini, Paul K Wallace, Kah Teong Soh, Hans Minderman, Orla Maguire, Tracey L O’ConnorSee the full list of authors
14 November 2023
